Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Lupus ; 27(5): 703-707, 2018 Apr.
Article in English | MEDLINE | ID: mdl-28992797

ABSTRACT

Hydroxychloroquine (HCQ) is widely used to treat autoimmune/rheumatic diseases such as systemic lupus erythematosus (SLE). The immune modulation effects of HCQ have been highlighted as beneficial for maintaining remission of SLE as well as ameliorating skin, joint and other manifestations. Moreover, HCQ exposure for prolonged periods as well as during pregnancy is considered safe, therefore it is recommended for the vast majority of SLE patients. Although HCQ therapy requires follow-up by a specialist, its most common side effects are mild gastrointestinal disturbances, sensitivity to light and skin rashes. Of these side effects, hypersensitivity skin reactions have been suggested to play a role in reduced compliance to HCQ therapy. In the current study we present a two-stage HCQ desensitization protocol that was successfully implemented among 12 out of 13 patients. We exhibit that prolonged HCQ oral desensitization is an effective method for overcoming mild to moderate late hypersensitivity reactions and thoroughly address possible mechanisms of action.


Subject(s)
Antirheumatic Agents/administration & dosage , Antirheumatic Agents/adverse effects , Desensitization, Immunologic/methods , Drug Eruptions/prevention & control , Hydroxychloroquine/administration & dosage , Hydroxychloroquine/adverse effects , Lupus Erythematosus, Systemic/drug therapy , Administration, Oral , Adult , Aged , Drug Administration Schedule , Drug Eruptions/diagnosis , Drug Eruptions/immunology , Female , Humans , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/immunology , Male , Middle Aged , Risk Factors , Severity of Illness Index , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...